Skip Ribbon Commands
Skip to main content
The Collaboration for AIDS Vaccine Discovery (CAVD) is an international network of scientists and experts dedicated to designing a variety of novel HIV vaccine candidates and advancing the most promising candidates to clinical trials.

The CAVD operates on the principle that accelerating progress toward an AIDS vaccine requires the creativity of individual investigators supported by a collaborative approach that emphasizes the sharing of scientific information and the standardization of laboratory techniques and data analysis.

Read more about the CAVD


Newly Available Publications

Below is a list of newly available publications, reporting research that received support under a CAVD grant. These articles have either appeared in print or are available as early release at a journal website. CAVD funding requires that all publications appear under Open Access terms, and are freely available without charge.
Please click on the title to see more information about the article, read its abstract, and link to the article’s record in PubMed.

For the full list of publications, click the following link.

Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trialJulg, B. and Stephenson, K.E.Nature Medicine5/12/2022Link to full-text


Funded by the:


In support of the:





© 2020 Bill & Melinda Gates Foundation. All Rights Reserved.

Privacy & Cookies Notice​ | Terms Of Use  |  Be Aware of Fraudulent Activity      ​


Funded by the:


Progress Report Summaries

Summaries of the annual and interim progress reports from the grants of 23 CAVD consortia are available at the link below. These summaries provide information on the important scientific progress being made by the CAVD researchers.

View Report Summaries


The CAVD Structure


More about the structure


In support of the:


For general questions about the CAVD or the content of the these pages, please contact
For technical issues with the website, please contact